Ipsen (FR:IPN) has released an update.
Ipsen has received positive CHMP opinions for two of its liver disease treatments, Iqirvo® for Primary Biliary Cholangitis and Kayfanda® for Alagille Syndrome, with EC decisions expected in Q3 2024. These potential new medicines, part of Ipsen’s rare disease portfolio, aim to address unmet medical needs and improve patients’ quality of life. The approvals could offer new therapy options for patients suffering from these rare cholestatic liver conditions.
For further insights into FR:IPN stock, check out TipRanks’ Stock Analysis page.
